131077-98-0

Usage

Uses

Used in Pharmaceutical Industry:
EFdA is used as an antiviral agent for the treatment of HIV and other retroviruses. Its high potency and ability to inhibit drug-resistant strains make it a promising candidate for the development of new antiviral therapies.
Used in HIV Treatment:
EFdA is used as a component of antiretroviral therapy for the treatment of HIV infection. Its unique mechanism of action and ability to inhibit drug-resistant strains contribute to its effectiveness in managing the disease and preventing the emergence of resistance.
Used in Research and Development:
EFdA is used in research and development for the study of its antiviral properties and potential applications in the treatment of other viral infections. Its unique structure and mechanism of action provide valuable insights for the development of new antiviral therapies.

InChI:InChI=1/C10H11F2N5O3/c11-7(12)6-4(18)5(19)10(20-6)17-2-16-3-8(13)14-1-15-9(3)17/h1-2,4-7,10,18-19H,(H2,13,14,15)/t4-,5+,6-,10+/m0/s1

Upstream product

• 43077-03-8 N⁶-benzoyl-5'-deoxy-2',3'-O-isopropylidiene-5',5'-(N,N'-diphenylethylenediamino)adenosine 
• 58-61-7 adenosine 
• 67662-04-8 N-benzoyl-N-(9-(6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide 
• 362-75-4 2',3'-isopropylidene adenosine 
• 119244-46-1 N⁶,N⁶-dibenzoyl-5'-deoxy-2',3'-O-isopropylidene-5',5'-(N,N'-diphenylethylenediamino)adenosine 
• 119244-34-7 N⁶,N⁶-dibenzoyl-5'deoxy-5',5'-difluoro-2',3'-O-isopropylideneadenosine 
• 119244-47-2 N⁶,N⁶-bis-benzoyl-2',3'-O-isopropylideneadenosine-5'-aldehyde 
• 134868-31-8 5'-deoxy-5',5'-difluoro-2',3'-O-isopropylideneadenosine 

Relevant academic research and scientific papers

Exploration of a potential difluoromethyl-nucleoside substrate with the fluorinase enzyme

The investigation of a difluoromethyl-bearing nucleoside with the fluorinase enzyme is described. 5′,5′-Difluoro-5′-deoxyadenosine 7 (F2DA) was synthesised from adenosine, and found to bind to the fluorinase enzyme by isothermal titration calorimetry with similar affinity compared to 5′-fluoro-5′-deoxyadenosine 2 (FDA), the natural product of the enzymatic reaction. F2DA 7 was found, however, not to undergo the enzyme catalysed reaction with l-selenomethionine, unlike FDA 2, which undergoes reaction with l-selenomethionine to generate Se-adenosylselenomethionine. A co-crystal structure of the fluorinase and F2DA 7 and tartrate was solved to 1.8 ?, and revealed that the difluoromethyl group bridges interactions known to be essential for activation of the single fluorine in FDA 2. An unusual hydrogen bonding interaction between the hydrogen of the difluoromethyl group and one of the hydroxyl oxygens of the tartrate ligand was also observed. The bridging interactions, coupled with the inherently stronger C-F bond in the difluoromethyl group, offers an explanation for why no reaction is observed.

5'-vinylhalo-aristeromycin/adenosine analogs and immunosuppressants

The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-vinylhalo-aristeromycin/adenosine analogs.

4',5'-Unsaturated 5'-Halogenated Nucleosides. Mechanism-Based and Competitive Inhibitors of S-Adenosyl-L-homocysteine Hydrolase

The design and synthesis of (E)- and (Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine (6 and 13, respectively), a new class of mechanism-based inhibitors of S-adenosyl-L-homocysteine (SAH) hydrolase, is described.A number of analogues of 6 and 13 were synt

5'-deoxy-4',5'-unsaturated-5'-substituted adenosines

This invention relates to certain aristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.